GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats

Metabolic Brain Disease

Volumn 30, Issue 2, 2015, Pages 519-527

  Sharma, Ajaykumar N ^a,b,c   Ligade, Sagar S ^a   Sharma, Jay N ^d   Shukla, Praveen ^e   Elased, Khalid M ^c   Lucot, James B ^c  

^a STES's Smt Kashibai Navale College of Pharmacy   (India)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c WRIGHT STATE UNIVERSITY   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Depression; GLP 1 receptor agonist; Liraglutide; Olanzapine

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIPRAMINE; LIRAGLUTIDE; OLANZAPINE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN SIZE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; FEMALE; FLUID INTAKE; FOOD INTAKE; FORCED SWIM TEST; GLUCOSE BLOOD LEVEL; IMMOBILITY; LOCOMOTION; LONG TERM CARE; METABOLIC DISORDER; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; AGONISTS; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; DRUG EFFECTS; EATING; METABOLIC DISEASES; MOTOR ACTIVITY; PSYCHOLOGY; SWIMMING; WISTAR RAT;

RATTUS;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; CHOLESTEROL; DEPRESSION; EATING; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPOGLYCEMIC AGENTS; IMIPRAMINE; LIRAGLUTIDE; METABOLIC DISEASES; MOTOR ACTIVITY; RATS; RATS, WISTAR; SWIMMING; TRIGLYCERIDES;

EID: 84924148527     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9591-7     Document Type: Article

References (58)

1. Abuirmeileh A, Harkavyi A, Rampersaud N, Lever R, Tadross JA, Bloom SR, Whitton PS (2012) Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat. J Pharm Pharmacol 64:637–643
2. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195–202
3. Barnes TR, McPhillips MA (1995) How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psychopharmacol 10(Suppl 3):115–121
4. Benedict C, Barclay JL, Ott V, Oster H, Hallschmid M (2013) Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men. Nutr Diabetes 3:e78
5. Brunetti L, Orlando G, Recinella L, Leone S, Ferrante C, Chiavaroli A, Lazzarin F, Vacca M (2008) Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus. Peptides 29:1377–1381
6. Buckley PF (2001) Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50:912–924
7. Caldwell CB, Gottesman II (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16:571–589
8. Coccurello, R., Moles, A., 2010. A murine model of atypical antipsychotic-induced weight gain and metabolic dysregulation. Curr. Protoc. Neurosci. Chapter 9, Unit9.
9. Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC (2006) Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 29:786–791
10. De AR, Carney MW (1969) Severe depressive mood changes following slow-release intramuscular fluphenazine injection. Br Med J 3:564–567
11. De HM, Correll CU, Cohen D (2010) Do antipsychotic medications reduce or increase mortality in schizophrenia? a critical appraisal of the FIN-11 study. Schizophr Res 117:68–74
12. De HM, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144–158
13. De HM, Detraux J, van WR, Yu W, Correll CU (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114–126
14. Dean CE (2006) Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 30:174–189
15. Dickerson F, Brown CH, Fang L, Goldberg RW, Kreyenbuhl J, Wohlheiter K, Dixon L (2008) Quality of life in individuals with serious mental illness and type 2 diabetes. Psychosomatics 49:109–114
16. Dixit TS, Sharma AN, Lucot JB, Elased KM (2013) Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol Behav 114–115:38–41
17. Ebdrup BH, Knop FK, Ishoy PL, Rostrup E, Fagerlund B, Lublin H, Glenthoj B (2012) Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 10:92
18. Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E (2013) The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38:1259–1270
19. Erreger K, Davis AR, Poe AM, Greig NH, Stanwood GD, Galli A (2012) Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav 106:574–578
20. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di MU, Perfetti R (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397–4408
21. Farwell WR, Stump TE, Wang J, Tafesse E, L’Italien G, Tierney WM (2004) Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 19:1200–1205
22. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC (2007) The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacol Berl 194:221–231
23. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ (2001) Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 35:187–191
24. Gromada J, Holst JJ, Rorsman P (1998) Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 435:583–594
25. Guedes EP, Madeira E, Mafort TT, Madeira M, Moreira RO, Mendonca LM, Godoy-Matos AF, Lopes AJ, Farias ML (2013) Body composition and depressive/anxiety symptoms in overweight and obese individuals with metabolic syndrome. Diabetol Metab Syndr 5:82
26. Harrow M, Grinker RR, Holzman PS, Kayton L (1977) Anhedonia and schizophrenia. Am J Psychiatry 134:794–797
27. Harrow M, Yonan CA, Sands JR, Marengo J (1994) Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 20:327–338
28. Herbener ES, Harrow M (2002) The course of anhedonia during 10 years of schizophrenic illness. J Abnorm Psychol 111:237–248
29. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011) Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68:128–137
30. Hoare E, Skouteris H, Fuller-Tyszkiewicz M, Millar L, Allender S (2014) Associations between obesogenic risk factors and depression among adolescents: a systematic review. Obes Rev 15:40–51
31. Isacson R, Nielsen E, Dannaeus K, Bertilsson G, Patrone C, Zachrisson O, Wikström L (2011) The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 650(1):249–255
32. Ishoy PL, Knop FK, Vilsboll T, Glenthoj BY, Ebdrup BH (2013) Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry 170:681–682
33. Ishoy PL, Knop FK, Broberg BV, Baandrup L, Fagerlund B, Jorgensen NR, Andersen UB, Rostrup E, Glenthoj BY, Ebdrup BH (2014) Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist–protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open 4:e004158
34. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacol Berl 182:220–231
35. Kim S, Moon M, Park S (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol 202:431–439
36. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J (1993) Depression in first-episode schizophrenia. Am J Psychiatry 150:1643–1648
37. Lando HM, Alattar M, Dua AP (2012) Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 18:472–477
38. Levitt Katz LE, Swami S, Abraham M, Murphy KM, Jawad AF, McKnight-Menci H, Berkowitz R (2005) Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children. Pediatr Diabetes 6:84–89
39. Lin PI, Shuldiner AR (2010) Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 123:234–243
40. Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS (2011) Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol 164:1410–1420
41. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB (2008) The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 103:94–103
42. Marmorstein, N.R., Iacono, W.G., Legrand, L., 2014. Obesity and depression in adolescence and beyond: reciprocal risks. Int. J. Obes. (Lond).
43. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337–345
44. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by abeta and iron. J Neurosci Res 72:603–612
45. Porsolt RD (1979) Animal model of depression. Biomedicine 30:139–140
46. Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton P (2012a) Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson’s disease with noradrenergic deficit. Br J Pharmacol 167:1467–1479
47. Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton PS (2012b) Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46:183–193
48. Rummel C, Kissling W, Leucht S (2005) Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res 80:85–97
49. Sharma AN, Elased KM, Garrett TL, Lucot JB (2010) Neurobehavioral deficits in db/db diabetic mice. Physiol Behav 101:381–388
50. Sharma AN, Elased KM, Lucot JB (2012) Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice. J Psychopharmacol 26:724–732
51. Siris SG (2000) Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry 157:1379–1389
52. Smith GC, Vickers MH, Shepherd PR (2011) Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem 117:241–249
53. Stonehouse AH, Darsow T, Maggs DG (2012) Incretin-based therapies. J Diabetes 4:55–67
54. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, Hattori N, Urabe T (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 31:1696–1705
55. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM (1998) Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43:2284–2290
56. Volavka J, Citrome L (2004) Olanzapine vs haloperidol for treatment of schizophrenia. JAMA 291:1064–1066
57. Whitehead C, Moss S, Cardno A, Lewis G (2003) Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med 33:589–599
58. Wise RA, Spindler J, deWit H, Gerberg GJ (1978) Neuroleptic-induced “anhedonia” in rats: pimozide blocks reward quality of food. Science 201:262–264